BBOT
BridgeBio Oncology TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Composite grade F from latest DB weights. Momentum 23.1 / Value 46.4
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
23
Value
46
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $25.30
Why
Momentum23 · Δ7d +25.7
Value46 · Δ7d +0.0
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
23
40% active weight
Current posture
7d trendImproving
Δ7d
+25.7
Δ21d
+28.5
Value
46
60% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.0
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 23.1 / Value 46.4
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$685.72M
Beta
-
Shares Out
80.11M
P/E (TTM)
56.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.02
Rev YoY
-
EPS YoY
+870.2%
Gross Margin
-
Op Margin
-
Net Debt
-$422.69M
Current Ratio
6.16
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology